Evidence map›Paper›PMID 40462831›Full record

ArticleInternational journal of nanomedicine2025

In vivo Targeted Delivery of Extracellular Vesicle‒Gold Nanorod Hybrids to Metastatic Melanoma Lung Tumors.

Karen Bolaños, Daniela León, Pedro Jara-Guajardo, Pamela Contreras, David Silva Ancahuail, Ana Luisa Riveros, Yanay Montano, Damián Pérez, Eyleen Araya, Marcelo J Kogan and 1 more

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Karen BolañosLaboratory of Cellular Communication, Center for Studies on Exercise, Metabolism and Cancer (CEMC), Program of Cell and Molecular Biology, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile.
Daniela LeónLaboratory of Cellular Communication, Center for Studies on Exercise, Metabolism and Cancer (CEMC), Program of Cell and Molecular Biology, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile.ORCID 0009-0009-5936-1592
Pedro Jara-GuajardoDepartamento de Quimica Farmacologica y Toxicologica, Facultad de Ciencias Quimicas y Farmaceuticas, Universidad de Chile, Santiago, Chile.
Pamela ContrerasLaboratory of Cellular Communication, Center for Studies on Exercise, Metabolism and Cancer (CEMC), Program of Cell and Molecular Biology, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile.
David Silva AncahuailAdvanced Center for Chronic Diseases (ACCDIS), Facultad de Medicina and Facultad de Ciencias Quimicas y Farmaceuticas, Santiago, Chile.
Ana Luisa RiverosDepartamento de Quimica Farmacologica y Toxicologica, Facultad de Ciencias Quimicas y Farmaceuticas, Universidad de Chile, Santiago, Chile.
Yanay MontanoDepartamento de Quimica Farmacologica y Toxicologica, Facultad de Ciencias Quimicas y Farmaceuticas, Universidad de Chile, Santiago, Chile.
Damián PérezDepartamento de Quimica Farmacologica y Toxicologica, Facultad de Ciencias Quimicas y Farmaceuticas, Universidad de Chile, Santiago, Chile.
Eyleen ArayaDepartamento de Ciencias Quimicas, Facultad de Ciencias Exactas, Universidad Andres Bello, Santiago, Chile.ORCID 0000-0003-0608-5087
Marcelo J KoganDepartamento de Quimica Farmacologica y Toxicologica, Facultad de Ciencias Quimicas y Farmaceuticas, Universidad de Chile, Santiago, Chile.
Andrew F G QuestLaboratory of Cellular Communication, Center for Studies on Exercise, Metabolism and Cancer (CEMC), Program of Cell and Molecular Biology, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cutaneous melanoma is an aggressive type of cancer characterized by rapid progression, resistance to chemotherapy, and metastasis to the lung. Conventional chemotherapy and radiotherapy are the principal approaches for treating metastasizing tumors, but the lack of targeting results in severe side effects and low treatment efficacy. Nanoparticles reportedly increase selectivity, given that they can accumulate at specific locations owing to the enhanced permeation and retention (EPR) effect. In this respect, plasmonic nanoparticles, such as gold nanorods (AuNRs), are interesting because of their photothermal and optical properties, making them suitable for biomedical applications, such as drug delivery, tumor ablation, and theranostics. To increase the tumor accumulation of AuNRs, extracellular vesicles (with sizes ranging from 40-150 nm) have attracted attention because of their remarkable biocompatibility and natural cell-accumulation selectivity. To further increase the targeting properties of the nanosystem, we functionalized the AuNRs with methotrexate (MTX), which is known to interact with the overexpressed folate receptors in cancer cells. We combined the inherent homing properties of exosomes from B16F10 cells with the active targeting properties of MTX to increase the accumulation of AuNRs in metastatic lung melanoma tumors. Methods: We obtained and exhaustively characterized B16F10 exosomes loaded with MTX-functionalized AuNRs (EXOS-AuNR-MTX). The safety of the complete nanosystem, as well as its specific and time-dependent accumulation in B16F10 cells, was determined using the mitochondrial MTS assay and fluorescence analysis, respectively. Results: Surface functionalization with MTX in combination with B16F10 EXOS was used to promote the accumulation of AuNRs in metastatic lung nodules, with significantly greater amounts of gold in the tumors following EXOS-AuNR-MTX treatment than following only AuNR-MTX treatment, as was determined in vivo and ex vivo by quantitative gold measurements. Remarkably, 5.5% of the injected dose of the AuNRs was recovered at the tumor sites, whereas only 1% of the injected dose usually accumulated in tumors due to the EPR effect, as reported. We further confirmed the preferential accumulation of AuNRs from EXOS-AuNR-MTX rather than from AuNR-MTX in tumor vessels and tumor nodules rather than healthy tissues by histological analysis. Conclusion: Our approach provides a valuable tool to improve the accumulation of gold nanoparticles in metastatic tumor nodules by combining the natural properties of exosomes to drive the targeting of AuNR-MTX.

Indexed as

Extracellular VesiclesGoldLung NeoplasmsMelanomaMelanoma, ExperimentalNanotubesAnimalsCell Line, TumorDrug Delivery SystemsExosomesMethotrexateMiceMice, Inbred C57BLGoldMethotrexatedrug deliveryexosomesgold nanorodsmetastasismethotrexatetargeting

Identifiers

PMID40462831
PMCPMC12132528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.